• American Oncology Network flagged multiple research studies slated for presentation at the ASCO 2026 meeting in Chicago, May 29–June 2.
• Key clinical-trial readouts include a phase 3 study of ZL-1310 in relapsed small cell lung cancer, positioning a potential new treatment option.
• Other studies focus on expanding outpatient use of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, aiming to broaden access in community settings.
• A separate program highlights an AI-enabled registry platform designed to scale clinical trials, pragmatic studies, and external control arms across US community practices.
• Additional abstracts address real-world outcomes and disparities in oncology care, signaling a strategic push into evidence generation beyond interventional trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Oncology Network Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280900PRIMZONEFULLFEED9727761) on May 28, 2026, and is solely responsible for the information contained therein.